These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1518433)

  • 1. Long-term efficacy and tolerability of octreotide treatment in acromegaly.
    Christensen SE; Weeke J; Orskov H; Kaal A; Lund E; Jørgensen J; Harris AG
    Metabolism; 1992 Sep; 41(9 Suppl 2):44-50. PubMed ID: 1518433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
    Ho KY; Weissberger AJ; Marbach P; Lazarus L
    Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of treatment with octreotide in acromegalic patients--a multicenter Italian study. Italian Multicenter Octreotide Study Group.
    Arosio M; Macchelli S; Rossi CM; Casati G; Biella O; Faglia G
    Eur J Endocrinol; 1995 Oct; 133(4):430-9. PubMed ID: 7581966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SMS 201-995 and thyroid function in acromegaly: acute, intermediate and long-term effects.
    Christensen SE; Weeke J; Kaal A; Harris AG; Orskov H
    Horm Metab Res; 1992 May; 24(5):237-9. PubMed ID: 1398464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.
    Newman CB; Melmed S; Snyder PJ; Young WF; Boyajy LD; Levy R; Stewart WN; Klibanski A; Molitch ME; Gagel RF
    J Clin Endocrinol Metab; 1995 Sep; 80(9):2768-75. PubMed ID: 7673422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients.
    Christensen SE; Weeke J; Orskov H; Møller N; Flyvbjerg A; Harris AG; Lund E; Jørgensen J
    Clin Endocrinol (Oxf); 1987 Sep; 27(3):297-306. PubMed ID: 2892599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ; Plöckinger U
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group.
    Vance ML; Harris AG
    Arch Intern Med; 1991 Aug; 151(8):1573-8. PubMed ID: 1872661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of high-dose octreotide (Sandostatin) by continuous subcutaneous infusion for the treatment of acromegaly.
    White MC; James RA; Chatterjee S; Mother M; Hall K; Dunne MJ; Baister ER; Kendall-Taylor P
    Horm Res; 1990; 33 Suppl 1():13-8; discussion 18-9. PubMed ID: 1972690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of octreotide delivered by continuous subcutaneous infusion with intermittent injection in the treatment of acromegaly.
    James RA; White MC; Chatterjee S; Marciaj H; Kendall-Taylor P
    Eur J Clin Invest; 1992 Aug; 22(8):554-61. PubMed ID: 1425862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of thyroid-stimulating hormone-secreting adenomas with octreotide.
    Chanson P; Warnet A
    Metabolism; 1992 Sep; 41(9 Suppl 2):62-5. PubMed ID: 1518435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four years' treatment of resistant acromegaly with octreotide.
    McKnight JA; McCance DR; Sheridan B; Atkinson AB
    Eur J Endocrinol; 1995 Apr; 132(4):429-32. PubMed ID: 7711880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneous responses to the long-term treatment of active acromegaly with octreotide.
    Chang CL; Kuo HF; Fang VS; Hwu CM; Lai TY; Yang HJ; Kwok CF; Ho LT
    Endocr J; 1996 Aug; 43(4):447-56. PubMed ID: 8930535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long-term treatment of acromegaly with the somatostatin analog octreotide (Sandostatin). On the predictive significance of acute tests].
    Schmidt K; Althoff PH; Harris A; Hofmeister-Wagner W; Schifferdecker E; Schöffling K
    Med Klin (Munich); 1990 Dec; 85(12):700-6. PubMed ID: 2128367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Behavior of the pituitary-thyroid axis in acromegalic subjects during prolonged intermittent and pulsatile treatment with octreotide].
    Cuttica CM; Fazzuoli L; Cariola G; Carraro A; Porcella E; Giusti M; Giordano G
    Recenti Prog Med; 1994 Jan; 85(1):7-12. PubMed ID: 8184183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous infusion of octreotide in acromegaly.
    James RA; Chatterjee S; White MC; Hall K; Moller N; Kendall-Taylor P
    Lancet; 1989 Nov; 2(8671):1083-7. PubMed ID: 2572807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Octreotide long term treatment of acromegaly: effect of drug withdrawal on serum growth hormone/insulin-like growth factor-I concentrations and on serum gastrin/24-hour intragastric pH values.
    Plöckinger U; Liehr RM; Quabbe HJ
    J Clin Endocrinol Metab; 1993 Jul; 77(1):157-62. PubMed ID: 8325938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly.
    Ho KK; Jenkins AB; Furler SM; Borkman M; Chisholm DJ
    Clin Endocrinol (Oxf); 1992 Mar; 36(3):271-9. PubMed ID: 1563080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.